DC
TEVA icon

Davenport & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Davenport & Co’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.72M Sell
80,284
-43,802
-35% -$1.46M 0.01% 505
2026
Q1 		$3.74M Sell
124,086
-88,651
-42% -$2.85M 0.02% 397
2025
Q4 		$6.64M Sell
212,737
-125,968
-37% -$3.1M 0.04% 291
2025
Q3 		$6.84M Sell
338,705
-24,817
-7% -$436K 0.04% 283
2025
Q2 		$6.09M Sell
363,522
-107,306
-23% -$1.73M 0.03% 294
2025
Q1 		$7.24M Buy
470,828
+89,340
+23% +$1.6M 0.04% 258
2024
Q4 		$8.41M Buy
381,488
+13,811
+4% +$251K 0.05% 241
2024
Q3 		$6.63M Sell
367,677
-4,981
-1% -$87.2K 0.04% 263
2024
Q2 		$6.06M Buy
372,658
+30,991
+9% +$477K 0.04% 270
2024
Q1 		$4.82M Buy
+341,667
New +$4.31M 0.03% 306
2022
Q4 		– Sell
-14,408
Closed -$116K – 1040
2022
Q3 		$116K Buy
+14,408
New +$127K ﹤0.01% 955
2021
Q4 		– Sell
-11,972
Closed -$117K – 1115
2021
Q3 		$117K Sell
11,972
-720
-6% -$6.74K ﹤0.01% 996
2021
Q2 		$126K Hold
12,692
– – ﹤0.01% 919
2021
Q1 		$146K Buy
12,692
+2,205
+21% +$25.3K ﹤0.01% 769
2020
Q4 		$101K Sell
10,487
-2,700
-20% -$25.9K ﹤0.01% 763
2020
Q3 		$119K Sell
13,187
-1,900
-13% -$20.1K ﹤0.01% 701
2020
Q2 		$186K Buy
15,087
+3,087
+26% +$34.9K ﹤0.01% 656
2020
Q1 		$108K Sell
12,000
-500
-4% -$5.12K ﹤0.01% 620
2019
Q4 		$123K Buy
+12,500
New +$112K ﹤0.01% 695
2017
Q4 		– Sell
-11,536
Closed -$203K – 723
2017
Q3 		$203K Sell
11,536
-14,270
-55% -$321K ﹤0.01% 627
2017
Q2 		$857K Sell
25,806
-157
-0.6% -$4.86K 0.01% 323
2017
Q1 		$941K Buy
25,963
+63
+0.2% +$2.15K 0.01% 298
2016
Q4 		$938K Sell
25,900
-6,593
-20% -$263K 0.01% 298
2016
Q3 		$1.5M Sell
32,493
-666
-2% -$34.7K 0.02% 238
2016
Q2 		$1.67M Sell
33,159
-2,697
-8% -$144K 0.03% 222
2016
Q1 		$1.92M Sell
35,856
-673,107
-95% -$39.5M 0.03% 205
2015
Q4 		$46.5M Buy
708,963
+12,867
+2% +$795K 0.75% 44
2015
Q3 		$39.3M Buy
696,096
+686
+0.1% +$44.5K 0.66% 57
2015
Q2 		$41.1M Buy
695,410
+8,122
+1% +$501K 0.64% 57
2015
Q1 		$42.8M Buy
687,288
+17,123
+3% +$996K 0.66% 49
2014
Q4 		$38.5M Sell
670,165
-9,944
-1% -$554K 0.62% 59
2014
Q3 		$36.6M Buy
680,109
+6,914
+1% +$366K 0.64% 55
2014
Q2 		$35.3M Sell
673,195
-504,129
-43% -$25.8M 0.6% 62
2014
Q1 		$62.2M Buy
1,177,324
+24,022
+2% +$1.11M 1.13% 21
2013
Q4 		$46.2M Buy
1,153,302
+483,708
+72% +$19M 0.86% 32
2013
Q3 		$25.3M Buy
669,594
+623,758
+1,361% +$24.3M 0.52% 76
2013
Q2 		$1.8M Buy
+45,836
New +$1.79M 0.04% 175

Other funds holding TEVA

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
SBCM
Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return
RA
Rockingstone Advisors Great Barrington, Massachusetts $249M AUM 31.06% 1-Year Est. Return

Davenport & Co's TEVA Position: Q2 2026 in Review

Davenport & Co reduced its Teva Pharmaceuticals (TEVA) stake by 35% in Q2 2026, selling an estimated $1.46M and leaving 80,284 shares worth $2.72M. The position accounts for 0.01% of the portfolio, ranked #505.

Davenport & Co first reported a position in TEVA in Q2 2013 and has held it in 37 quarters since. The position peaked at $62.2M in Q1 2014. 72 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Davenport & Co held 80,284 shares of Teva Pharmaceuticals worth $2.72M as of Q2 2026.
  • Davenport & Co sold 43,802 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.46M.
  • Teva Pharmaceuticals made up 0.01% of Davenport & Co's portfolio in Q2 2026, its #505 holding.
  • Davenport & Co first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 37 quarters since.
  • Davenport & Co's Teva Pharmaceuticals position peaked at $62.2M in Q1 2014.
  • 72 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.